Disease · MONDO_0003835

gastric cardia adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric cardia adenocarcinoma. Diseases, record MONDO_0003835. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003835

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric cardia adenocarcinoma; Open Targets
Open Targets ID: MONDO_0003835; Open Targets
Other names: adenocarcinoma of cardia of stomach, adenocarcinoma of the cardia of the stomach, adenocarcinoma of the gastric cardia, cardia of stomach adenocarcinoma; Open Targets
Disease Ontology: DOID:6271; Disease Ontology
NCI Thesaurus: C5247; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 11 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LAPATINIB	CHEMBL554	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00938470	Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction	Phase 2	73	2017-04-10	Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer	CAPECITABINE, DOCETAXEL, FLUOROURACIL, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00591123	Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia	Phase 2	38	2021-10-01	Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia	ERLOTINIB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02730546	Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery	Phase 1/2	31	2022-08-25	Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7	CARBOPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02037048	FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma	Phase 2	63		Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer	CARBOPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00040859	Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer	Phase 2	48		Esophageal Cancer, Gastric Cancer	CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00003748	Irinotecan in Treating Patients With Esophageal or Stomach Cancer	Phase 2	40		Esophageal Cancer, Gastric Cancer	IRINOTECAN	Its record names the disease	ClinicalTrials.gov
NCT00259987	Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus	Phase 2	24		Adenocarcinoma	LAPATINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Arm I (DOC, 5FU/O/RT, Surgery) vs Arm II (5FU/O/RT, Surgery): serious adverse events	7 of 34	7 of 28	62	NCT00938470

Source Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16303863	RESULT	1	PubMed
33934058	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003835

GET https://conductscience.org/api/diseases/v1/MONDO_0003835/drugs

API reference For AI assistants